CoChat
Sign Up
Cited by 203

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease

Barcia, C, Ros, C M, Annese, V, Gómez, A, Ros-Bernal, F, Aguado-Llera, D, Martínez-Pagán, M E, de Pablos, V, Fernandez-Villalba, E, Herrero, M T·2011·Cell Death & Disease
DOI 10.1038/cddis.2011.17PMC PMC3122054
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/cddis.2011.17

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Persistent increase of IFN-γ and TNF-α in chronic Parkinsonian monkeys. (a–d) Artist's sketch (a) of the typical gait posture of a normal monkey (control) compared with the characteristic Parkinsonian posture (Parkinsonian). Parkinsonian monkey posture is characterized by curvature of the trunk and rigidity of the limbs, together with rigidity of the tail (drawings by C.B). (b) Graphs of the motor score impairment reached by the MPTP-treated monkeys included in the study. Some animals, despite MPTP administration, did not show symptoms (asymptomatic). (c) Levels of IFN-γ measured by ELISA in serum increase in Parkinsonian monkeys. (d) Levels of TNF-α measured by ELISA in serum are increased in Parkinsonian monkeys. *P<0.05 respect to non-Parkinsonian
Figure 1 Persistent increase of IFN-γ and TNF-α in chronic Parkinsonian monkeys. (a–d) Artist's sketch (a) of the typical gait posture of a normal monkey (control) compared with the characteristic Parkinsonian posture (Parkinsonian). Parkinsonian monkey posture is characterized by curvature of the trunk and rigidity of the limbs, together with rigidity of the tail (drawings by C.B). (b) Graphs of the motor score impairment reached by the MPTP-treated monkeys included in the study. Some animals, despite MPTP administration, did not show symptoms (asymptomatic). (c) Levels of IFN-γ measured by ELISA in serum increase in Parkinsonian monkeys. (d) Levels of TNF-α measured by ELISA in serum are increased in Parkinsonian monkeys. *P<0.05 respect to non-ParkinsonianCC BY-NC-ND · PubMed Central
Figure 2 Increase of IFN-γ in the SNpc of Parkinsonian monkeys. (a–f): Increase of IFN-γ+ cells in brain sections of the SNpc of Parkinsonian monkeys. (a) Confocal images of immunofluorescence against IFN-γ revealed a higher number of IFN-γ+ cells in MPTP-treated animals. Scale bar: 100 μm. (b) The density of cells was estimated by stereological criteria and a significant increase in IFN-γ+ cells was observed in MPTP-treated animals. (c) Western blot of IFN-γ from monkey brain samples. Tissue of the SNpc from seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein. The analysis of the optical density of all the studied monkeys, normalized with GAPDH, is represented in Table 2. (d) Multiple fluorescence labeling revealed that IFN-γ (red) co-localize with microglial marker Iba-1 (green) (1). However, astrocyte marker GFAP (green) did not co-localize with IFN-γ-expressing cells (red) (2). DAPI staining was used to mark the cell nuclei (Blue). Scale bar: 50 μm. (e) Higher magnification of two representative IFN-γ+ microglial cells. Some of the microglial cells with resting phenotype (1) presented IFN-γ staining mainly confined to the cytoplasm (red) surrounding the cell nucleus (Blue). Other microglial cells with activated phenotype (2) presented IFN-γ staining through the whole cytoplasm. (f) Percentage of IFN-γ-expressing microglia (black pie portion (Iba-1+/IFN-γ+ cells)) over the rest of the microglial population (gray pie portion (Iba-1+/IFN-γ− cells)) in the three group of animals. *P<0.05 (one-way ANOVA and Tukey's test)
Figure 2 Increase of IFN-γ in the SNpc of Parkinsonian monkeys. (a–f): Increase of IFN-γ+ cells in brain sections of the SNpc of Parkinsonian monkeys. (a) Confocal images of immunofluorescence against IFN-γ revealed a higher number of IFN-γ+ cells in MPTP-treated animals. Scale bar: 100 μm. (b) The density of cells was estimated by stereological criteria and a significant increase in IFN-γ+ cells was observed in MPTP-treated animals. (c) Western blot of IFN-γ from monkey brain samples. Tissue of the SNpc from seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein. The analysis of the optical density of all the studied monkeys, normalized with GAPDH, is represented in Table 2. (d) Multiple fluorescence labeling revealed that IFN-γ (red) co-localize with microglial marker Iba-1 (green) (1). However, astrocyte marker GFAP (green) did not co-localize with IFN-γ-expressing cells (red) (2). DAPI staining was used to mark the cell nuclei (Blue). Scale bar: 50 μm. (e) Higher magnification of two representative IFN-γ+ microglial cells. Some of the microglial cells with resting phenotype (1) presented IFN-γ staining mainly confined to the cytoplasm (red) surrounding the cell nucleus (Blue). Other microglial cells with activated phenotype (2) presented IFN-γ staining through the whole cytoplasm. (f) Percentage of IFN-γ-expressing microglia (black pie portion (Iba-1+/IFN-γ+ cells)) over the rest of the microglial population (gray pie portion (Iba-1+/IFN-γ− cells)) in the three group of animals. *P<0.05 (one-way ANOVA and Tukey's test)CC BY-NC-ND · PubMed Central
Figure 3 Microglial and astroglial cells express IFN-γR in the SNpc of MPTP-treated monkeys. (a and b) Sections of the SNpc of MPTP-treated monkeys were immuno-stained for IFN-γR (Green), combined with either astrocyte marker GFAP (Red in a) or microglial marker Iba-1 (Red in b) and counterstained with DAPI (Blue). Scale bars: in a, 50 μm; in b, 40 μm
Figure 3 Microglial and astroglial cells express IFN-γR in the SNpc of MPTP-treated monkeys. (a and b) Sections of the SNpc of MPTP-treated monkeys were immuno-stained for IFN-γR (Green), combined with either astrocyte marker GFAP (Red in a) or microglial marker Iba-1 (Red in b) and counterstained with DAPI (Blue). Scale bars: in a, 50 μm; in b, 40 μmCC BY-NC-ND · PubMed Central
Figure 4 Persistent phosphorylation of STAT1 (pSTAT1) in the SNpc of chronic Parkinsonian monkeys. (a–e) Panel (a) shows confocal images of pSTAT1 in a representative image of the SNpc of a control monkey, asymptomatic and Parkinsonian monkey. DAPI staining is combined to observe the cell nuclei (Blue). High levels of pSTAT1 staining (Red) can be seen in Parkinsonian monkeys. Scale bar: 100 μm. (b) Quantification of pSTAT1+ cells in the SNpc of control, asymptomatic and Parkinsonian monkeys. A strongly significant increase can be observed in Parkinsonian monkeys. **P<0.01 (one-way ANOVA and Tukey's test). (c) The pSTAT1 immunostaining in the SNpc identified astroglia-like cells (1) and microglia-like cells (2). Scale bar: 30 μm. (d) The pSTAT1 immunostaining (Red) was combined with GFAP or Iba-1 antibodies (Green) and both astrocytes (GFAP) and microglia (Iba-1) were seen to co-localize with pSTAT1. Nuclei were stained with DAPI (Blue). Scale bar: 20 μm. (e) Illustration of the IFN-γ signaling, characterized by the phosphorylation of STAT1, through the activation of IFN-γ receptor (IFN-γR) in a microglial cell and an astrocyte
Figure 4 Persistent phosphorylation of STAT1 (pSTAT1) in the SNpc of chronic Parkinsonian monkeys. (a–e) Panel (a) shows confocal images of pSTAT1 in a representative image of the SNpc of a control monkey, asymptomatic and Parkinsonian monkey. DAPI staining is combined to observe the cell nuclei (Blue). High levels of pSTAT1 staining (Red) can be seen in Parkinsonian monkeys. Scale bar: 100 μm. (b) Quantification of pSTAT1+ cells in the SNpc of control, asymptomatic and Parkinsonian monkeys. A strongly significant increase can be observed in Parkinsonian monkeys. **P<0.01 (one-way ANOVA and Tukey's test). (c) The pSTAT1 immunostaining in the SNpc identified astroglia-like cells (1) and microglia-like cells (2). Scale bar: 30 μm. (d) The pSTAT1 immunostaining (Red) was combined with GFAP or Iba-1 antibodies (Green) and both astrocytes (GFAP) and microglia (Iba-1) were seen to co-localize with pSTAT1. Nuclei were stained with DAPI (Blue). Scale bar: 20 μm. (e) Illustration of the IFN-γ signaling, characterized by the phosphorylation of STAT1, through the activation of IFN-γ receptor (IFN-γR) in a microglial cell and an astrocyteCC BY-NC-ND · PubMed Central
Figure 5 Persistent increase of TNF-α in the CNS of chronic Parkinsonian monkeys. (a–f) Increase of TNF-α+ cells in the SNpc of Parkinsonian monkeys. (a) Confocal images of immunofluorescence against TNF-α revealed higher levels in Parkinsonian animals. Scale bar: 100 μm. (b) The density of cells was estimated by stereological criteria and a significant increase of TNF-α+ cells were observed in Parkinsonian animals. (c) Western blot of TNF-α from monkey brain samples. Tissue of the SNpc from seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein. TNF-α was specifically detected in the expected band in the SNpc of MPTP-treated monkeys. The quantification of the optical density of all the analyzed monkeys, normalized with GAPDH, is represented in Table 2. (d) Multiple fluorescence labeling revealed that TNF-α (red) did not co-localize with microglial marker Iba-1 (green) (1). However, astrocyte marker GFAP (green) co-localized with TNF-α-expressing cells (red) (2). DAPI staining was used to mark the cell nuclei (Blue). Scale bar: 25 μm. (e) Higher magnification of a representative TNF-α+ astrocyte. (f) Percentage of TNF-α-expressing astrocytes (black pie portion (GFAP+/TNF-α+ cells)) over the rest of the astroglial population (gray pie portion (GFAP+/TNF-α− cells)) in the three group of animals. *P<0.05 (one-way ANOVA and Tukey's test)
Figure 5 Persistent increase of TNF-α in the CNS of chronic Parkinsonian monkeys. (a–f) Increase of TNF-α+ cells in the SNpc of Parkinsonian monkeys. (a) Confocal images of immunofluorescence against TNF-α revealed higher levels in Parkinsonian animals. Scale bar: 100 μm. (b) The density of cells was estimated by stereological criteria and a significant increase of TNF-α+ cells were observed in Parkinsonian animals. (c) Western blot of TNF-α from monkey brain samples. Tissue of the SNpc from seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein. TNF-α was specifically detected in the expected band in the SNpc of MPTP-treated monkeys. The quantification of the optical density of all the analyzed monkeys, normalized with GAPDH, is represented in Table 2. (d) Multiple fluorescence labeling revealed that TNF-α (red) did not co-localize with microglial marker Iba-1 (green) (1). However, astrocyte marker GFAP (green) co-localized with TNF-α-expressing cells (red) (2). DAPI staining was used to mark the cell nuclei (Blue). Scale bar: 25 μm. (e) Higher magnification of a representative TNF-α+ astrocyte. (f) Percentage of TNF-α-expressing astrocytes (black pie portion (GFAP+/TNF-α+ cells)) over the rest of the astroglial population (gray pie portion (GFAP+/TNF-α− cells)) in the three group of animals. *P<0.05 (one-way ANOVA and Tukey's test)CC BY-NC-ND · PubMed Central
Figure 6 IFN-γ and TNF-α have a cell specific function in microglial and astroglial activation. (a–f) Activation of the microglia depends on IFN-γ and activation of the astrocytes depends on TNF-α. (a) Quantification of TH+ neurons in the SNpc revealed no significant reduction of dopaminergic neurons in any of the experimental groups 24 h after MPTP. (b) Quantification of the number of F4/80+ microglial cells and GFAP+ astroglial cells. In the absence of IFN-γ, no increase in the number of F4/80+ or GFAP+ cells was observed after MPTP treatment. In the absence of TNF-α, a slight increase of F4/80+ cells was observed, but no changes were noted in the number of GFAP+ cells. *P<0.05 (one-way ANOVA and Tukey's test). (c) Confocal pictures of microglial cells (Iba-1) and astroglial cells (GFAP) in the SNpc of wild type mice (C57 BL6), IFN-γ KO mice (IFNγ(−/−)) and TNF-α KO mice (TNF-α(−/−)). Scale bar: 30 μm. (d) Quantification of the area occupied by Iba-1 demonstrates that the size of microglial cells (Iba-1) increases significantly after MPTP treatment. However, in the absence of IFN-γ, the microglial cells do not change their size. In TNF-α(−/−) mice, microglial cells also increase their size, but to a lesser extent. Quantification of the area occupied by GFAP demonstrated that the size of astroglial cells increases after MPTP treatment. In the absence of IFN-γ, astroglial cells also increase their size after MPTP; however, in the absence of TNF-α, astroglial cells remain unchanged after MPTP. *P<0.01 with respect to control saline values, †P<0.01 with respect to wild type C57 MPTP (one-way ANOVA and Tukey's test). (e) Quantification of primary branches (1ary), secondary branches (2ary) and terminal tips (T) in microglial (Iba-1) and astroglial cells (GFAP). Both microglial and astroglial cells change their phenotype 24 h after MPTP treatment in wild-type animals (C57BL6). In animals without IFN-γ (IFNγ(−/−)), microglial cells show no changes in primary branches, but increased numbers of secondary branches and terminal tips. In TNF-α KO animals (TNFα(−/−)), microglial cells show increased numbers of primary, secondary branches and T. However, astroglial cells remain unchanged in TNF-α(−/−) mice 24 h after MPTP. *P<0.01, ▾P<0.05 (one-way ANOVA and Dunnett's test)
Figure 6 IFN-γ and TNF-α have a cell specific function in microglial and astroglial activation. (a–f) Activation of the microglia depends on IFN-γ and activation of the astrocytes depends on TNF-α. (a) Quantification of TH+ neurons in the SNpc revealed no significant reduction of dopaminergic neurons in any of the experimental groups 24 h after MPTP. (b) Quantification of the number of F4/80+ microglial cells and GFAP+ astroglial cells. In the absence of IFN-γ, no increase in the number of F4/80+ or GFAP+ cells was observed after MPTP treatment. In the absence of TNF-α, a slight increase of F4/80+ cells was observed, but no changes were noted in the number of GFAP+ cells. *P<0.05 (one-way ANOVA and Tukey's test). (c) Confocal pictures of microglial cells (Iba-1) and astroglial cells (GFAP) in the SNpc of wild type mice (C57 BL6), IFN-γ KO mice (IFNγ(−/−)) and TNF-α KO mice (TNF-α(−/−)). Scale bar: 30 μm. (d) Quantification of the area occupied by Iba-1 demonstrates that the size of microglial cells (Iba-1) increases significantly after MPTP treatment. However, in the absence of IFN-γ, the microglial cells do not change their size. In TNF-α(−/−) mice, microglial cells also increase their size, but to a lesser extent. Quantification of the area occupied by GFAP demonstrated that the size of astroglial cells increases after MPTP treatment. In the absence of IFN-γ, astroglial cells also increase their size after MPTP; however, in the absence of TNF-α, astroglial cells remain unchanged after MPTP. *P<0.01 with respect to control saline values, †P<0.01 with respect to wild type C57 MPTP (one-way ANOVA and Tukey's test). (e) Quantification of primary branches (1ary), secondary branches (2ary) and terminal tips (T) in microglial (Iba-1) and astroglial cells (GFAP). Both microglial and astroglial cells change their phenotype 24 h after MPTP treatment in wild-type animals (C57BL6). In animals without IFN-γ (IFNγ(−/−)), microglial cells show no changes in primary branches, but increased numbers of secondary branches and terminal tips. In TNF-α KO animals (TNFα(−/−)), microglial cells show increased numbers of primary, secondary branches and T. However, astroglial cells remain unchanged in TNF-α(−/−) mice 24 h after MPTP. *P<0.01, ▾P<0.05 (one-way ANOVA and Dunnett's test)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 38

  1. Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW . Astrocytes and Parkinson's disease. Prog Brain Res 1992; 94: 429–436. · DOI
  2. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D . Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598–605. · DOI · Paper page
  3. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A et al. Evidence of active microglia in substantia nigra pars compacta of Parkinsonian monkeys 1 year after MPTP exposure. Glia 2004; 46: 402–409. · DOI
  4. Benveniste EN, Kwon J, Chung WJ, Sampson J, Pandya K, Tang LP . Differential modulation of astrocyte cytokine gene expression by TGF-beta. J Immunol 1994; 153: 5210–5221. · DOI
  5. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C . Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993; 7: 75–83. · DOI
  6. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R et al. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 2007; 27: 3328–3337. · DOI
  7. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009; 23: 55–63. · DOI · Paper page
  8. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T . Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett 1994; 165: 208–210. · DOI · Paper page
  9. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O’Callaghan JP . Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 2002; 16: 1474–1476. · DOI
  10. Ferger B, Leng A, Mura A, Hengerer B, Feldon J . Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 2004; 89: 822–833. · DOI
  11. Barcia C, de Pablos V, Bautista-Hernandez V, Sanchez-Bahillo A, Bernal I, Fernandez-Villalba E et al. Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord 2005; 11: 435–439. · DOI
  12. Vazquez-Claverie M, Garrido-Gil P, San Sebastian W, Izal-Azcarate A, Belzunegui S, Marcilla I et al. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. J Neuropathol Exp Neurol 2009; 68: 977–984. · DOI
  13. Hashioka S, Klegeris A, Schwab C, McGeer PL . Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging 2009; 30: 1924–1935. · DOI
  14. Tsuda M, Masuda T, Kitano J, Shimoyama H, Tozaki-Saitoh H, Inoue K . IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc Natl Acad Sci USA 2009; 106: 8032–8037. · DOI
  15. Vega C, Pellerin L, Dantzer R, Magistretti PJ . Long-term modulation of glucose utilization by IL-1 alpha and TNF-alpha in astrocytes: Na+ pump activity as a potential target via distinct signaling mechanisms. Glia 2002; 39: 10–18. · DOI
  16. Kipp M, Karakaya S, Johann S, Kampmann E, Mey J, Beyer C . Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in midbrain astrocytes. J Neuroendocrinol 2007; 19: 819–822. · DOI · Paper page
  17. Lung HL, Leung KN, Stadlin A, Ma CM, Tsang D . Induction of tumor necrosis factor receptor type 2 gene expression by tumor necrosis factor-alpha in rat primary astrocytes. Life Sci 2001; 68: 2081–2091. · DOI
  18. Scalzo P, Kummer A, Cardoso F, Teixeira AL . Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009; 216: 122–125. · DOI
  19. Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ . Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008; 131 (Part 7): 1880–1894. · DOI · Paper page
  20. Kurkowska-Jastrzebska I, Balkowiec-Iskra E, Ciesielska A, Joniec I, Cudna A, Zaremba MM et al. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease. Int Immunopharmacol 2009; 9: 781–791. · DOI
  21. Luchtman DW, Shao D, Song C . Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav 2009; 98: 130–138. · DOI
  22. Hebert G, Arsaut J, Dantzer R, Demotes-Mainard J . Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 2003; 349: 191–195. · DOI
  23. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182–192.
  24. Bogdan C, Schleicher U . Production of interferon-gamma by myeloid cells--fact or fancy? Trends Immunol 2006; 27: 282–290. · DOI
  25. Puddu P, Fantuzzi L, Borghi P, Varano B, Rainaldi G, Guillemard E et al. IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages. J Immunol 1997; 159: 3490–3497. · DOI
  26. Munder M, Mallo M, Eichmann K, Modolell M . Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998; 187: 2103–2108. · DOI
  27. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009; 137: 47–59. · DOI · Paper page
  28. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC . Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999; 28: 114–127. · DOI
  29. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC . Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172: 151–154. · DOI
  30. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann neurol 2005; 58: 963–967. · DOI
  31. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat genet 2010; 42: 781–785. · DOI
  32. Kopf M, Bachmann MF, Marsland BJ . Averting inflammation by targeting the cytokine environment. Nat rev 2010; 9: 703–718.
  33. Herrero MT, Hirsch EC, Kastner A, Ruberg M, Luquin MR, Laguna J et al. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 1993; 56: 499–511. · DOI
  34. Paxinos GC, Franklin KBJ . The mouse brain in stereotaxic coordinates. Academic Press: New York, 2001.
  35. Paxinos G, Xu-Feng H, Toga A . The Rhesus Monkey Brain in Stereotaxic Coordinates. Academic Press: San Diego, 1999.
  36. Olzewski J., Baxter D . In: Boyd JD (ed.). Cytoarchitecture of the Human Brainstem S. Karger, Lippincott Company: Philadelphia and Montreal, 1954.
  37. Damier P, Hirsch EC, Agid Y, Graybiel AM . The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122 (Part 8): 1437–1448. · DOI
  38. Barcia C, Thomas CE, Curtin JF, King GD, Wawrowsky K, Candolfi M et al. In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med 2006; 203: 2095–2107. · DOI

Cited by

Sorted by citations

See all 203

Metadata

Authors
Barcia, C., Ros, C. M., Annese, V, Gómez, A., Ros-Bernal, F., Aguado-Llera, D., Martínez-Pagán, M. E., de Pablos, V, Fernandez-Villalba, E., & Herrero, M. T.
Venue
Cell Death & Disease
Publisher
Springer Science and Business Media LLC
Published
2011-04-07
Volume
2
Issue
4
Pages
e142-e142
ISSN
2041-4889
DOI
10.1038/cddis.2011.17
PMC
PMC3122054
Cited by
203
References
2
Language
en
Update notices
erratum (2012-08-23)
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. https://app.cochat.ai/papers/10.1038/cddis.2011.17
The paper
Barcia, C., Ros, C. M., Annese, V, Gómez, A., Ros-Bernal, F., Aguado-Llera, D., Martínez-Pagán, M. E., de Pablos, V, Fernandez-Villalba, E., & Herrero, M. T. (2011). IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death & Disease. https://doi.org/10.1038/cddis.2011.17